Adam Crystal
President, R&D · 8 filings · Latest: Jun 1, 2026
Tango Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
TNGX | Adam Crystal | President, R&D | Jun 1, 2026 | Sale | $22.87 | 27,000 | $617.6K | 115,743 | |
TNGX | Adam Crystal | President, R&D | Jun 1, 2026 | Option Exercise | $5.20 | 27,000 | $140.4K | 142,743 | |
TNGX | Adam Crystal | President, R&D | May 1, 2026 | Sale | $21.23 | 27,000 | $573.1K | 115,743 | |
TNGX | Adam Crystal | President, R&D | May 1, 2026 | Option Exercise | $5.20 | 27,000 | $140.4K | 142,743 | |
TNGX | ADAM CRYSTAL | — | May 1, 2026 | Proposed Sale | $21.62 | 65,460 | $1.4M | — | |
TNGX | Adam Crystal | President, R&D | Apr 15, 2026 | Sale | $25.00 | 38,460 | $961.5K | 112,622 | |
TNGX | Adam Crystal | President, R&D | Apr 15, 2026 | Option Exercise | $5.20 | 38,460 | $200.0K | 151,082 | |
TNGX | Adam Crystal | President, R&D | Apr 1, 2026 | Sale | $21.20 | 27,000 | $572.5K | 112,622 | |
TNGX | Adam Crystal | President, R&D | Apr 1, 2026 | Option Exercise | $5.20 | 27,000 | $140.4K | 139,622 | |
TNGX | Adam Crystal | President, R&D | Mar 25, 2026 | Sale | $20.11 | 12,000 | $241.3K | 112,622 | |
TNGX | Adam Crystal | President, R&D | Mar 25, 2026 | Option Exercise | $5.20 | 12,000 | $62.4K | 124,622 | |
TNGX | ADAM CRYSTAL | — | Mar 25, 2026 | Proposed Sale | $19.48 | 93,000 | $1.8M | — | |
TNGX | Adam Crystal | President, R&D | Mar 5, 2026 | Sale | $15.00 | 20,251 | $303.8K | 112,622 | |
TNGX | ADAM CRYSTAL | — | Mar 5, 2026 | Proposed Sale | $12.35 | 20,251 | $250.1K | — | |
TNGX | Adam Crystal | President, R&D | Feb 25, 2026 | Sale | $12.77 | 54,345 | $694.2K | 132,873 | |
TNGX | ADAM CRYSTAL | — | Feb 25, 2026 | Proposed Sale | $12.88 | 54,345 | $700.0K | — | |
TNGX | Adam Crystal | President, R&D | Feb 3, 2026 | Sale | $12.26 | 18,452 | $226.3K | 187,218 |